Trial
NCT04748419
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
AstraZeneca
Condition
Lung Cancer
Intervention
consolidative hypofractionated radiation therapy (hfRT)
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-05